Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Alon Ben-Noon | Co-Founder, CEO & Director | 660k | -- | 1979 |
| Mr. Or Eisenberg | Chief Financial Officer | 382k | -- | 1981 |
| Ms. Hagit Binder | Chief Operation Officer | 232.62k | -- | 1978 |
| Dr. Niva Russek-Blum Ph.D. | Chief Technology Officer | 223.62k | -- | 1979 |
| Dr. Ferenc Tracik M.D. | Chief Medical Officer | 532k | -- | 1964 |
| Ms. Yael Barak | VP of Quality & Compliance | -- | -- | 1970 |
| Ms. Keren Pushett | Head of HR | -- | -- | -- |
| Mr. Eidan Loushi | C.R.A. | -- | -- | -- |
NeuroSense Therapeutics Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 18
Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available